The dependence on protein kinase C (PKC) of arachidonic acid (AA) metabolism stimulated by the biologically important oxidant HzOz, as compared to zymosan particles, was investigated in the rat alveolar macrophage. The PKC inhibitor staurosporine markedly reduced AA release and eicosanoid synthesis stimulated by zymosan, but only slightly inhibited AA release and metabolism induced by H202. Furthermore, in macrophages depleted of PKC by extended exposure to phorbol 1Zmyristate 13-acetate, AA release in response to zymosan was greatly inhibited, whereas that stimulated by H20z was attenuated to a significantly lesser degree. Thus, zymosan-stimulated AA metabolism requires active PKC, whereas H,O,-induced metabolism is largely PKC-independent. This provides direct evidence for the existence of two pathways of agonist-stimulated AA metabolism, which differ in their dependence on PKC, in the alveolar macrophage.
dence of AA metabolism stimulated by different kinds of agonists within a particular cell type.
We have previously demonstrated that noncytolytic doses of H,O,, a major reactive oxygen species released by activated inflammatory cells and an important mediator of oxidant tissue injury [lo] , have the capacity to stimulate the release of AA and its metabolism to cyclooxygenase (but not 5-lipoxygenase) eicosanoids in the cultured rat alveolar macrophage (AM) [11, 12] . We have also found that, in contrast to AA metabolism stimulated by the particulate zymosan [13, 14] or by Ca*+ ionophore A23187 [15] , H,O,-induced AA metabolism is not inhibited by glucocorticoids [16] . One possible explanation for the failure of glucocorticoids to inhibit H,O,-induced AA metabolism is that H,O, might release AA from cellular phospholipids by a different enzymatic mechanism that do zymosan and A23187, both of which activate AA deacylation via Ca2+-dependent phospholipase A, (PLA,) [17, 18] . To further elucidate the mechanism(s) by which H,02 initiates macrophage AA metabolism, we studied the PKC dependence of AA release and eicosanoid synthesis in response to H,O,, as compared to zymosan, in the rat AM. Our results indicate that zymosan and H,O, stimulate AA release and metabolism by pathways which differ markedly in their dependence on PKC. [STAUROSPORINE] (nM) Fig. 1 Fig. 2 , zymosan stimulated synthesis of the cyclooxygenase metabolites thromboxane (Tx)B,, prostaglandin (PG)E,, and 12-hydroxy-5,8,10-heptadecatrienoic acid (HHT) and the 5-lipoxygenase products leukotriene (LT)B,, LTC,, and 5-hydroxyeicosatetraenoic acid (5-HETE) ( Fig. 2A) , whereas H,O, stimulated formation of TxB, and HHT and no 5-lipoxygenase products (Fig. 2C) , as previously reported [11, 12] . Fig. 2 On the other hand, the inactive phorbol ester PDD, which does not deplete PKC, had very little inhibitory effect on [3H]AA release in response to either zymosan or H,O, (Fig. 3) , indicating that the inhibition seen with PMA was specifically related to its effects on PKC.
Our finding that both staurosporine and PMA pretreatment inhibit AA release and that staurosporine also inhibits eicosanoid synthesis in response to zymosan confirm that zymosan-induced AA metabolism requires active PKC in the rat AM, as previously demonstrated for other macrophage populations [5, 6 ]. In contrast, however, the release of free AA stimulated by H,O, was not affected by staurosporine, even at a concentration (100 nM) 4-fold greater than that which maximally inhibited zymosan-induced AA release ( Fig.  1) and 5-fold greater than that shown to maximally inhibit partially purified rat brain PKC [20] . This result could not be attributed to direct chemical inactivation of staurosporine by H202. In addition, PMA-induced down-regulation of PKC reduced H,O,-stimulated AA release to a significantly lesser degree than that stimulated by zymosan (Fig. 3) . Taken together, these results indicate the H,O,-stimulated AA release and eicosanoid synthesis are much less dependent on active PKC than zymosan-induced AA metabolism, implying that H,O, triggers AA release, at least in part, by a pathway which does not require active PKC. Thus, we have provided direct evidence for the existence of two pathways of agonist-stimulated AA metabolism, which differ in their dependence on PKC, in the AM. This finding extends the concept of agonist-specific heterogeneity in macrophage AA metabolism to regulation by PKC. Since PKC plays an important role in regulating Ca2+-dependent cellular processes [25] , and zymosan is believed to release AA in macrophages via a Ca2+-dependent PLA, [17] , the strong PKC dependence of zymosan-induced AA metabolism suggests that PKC may be required for activation of PLA, in the macrophage. On the other hand, the relative lack of PKC dependence of H,O,-induced AA metabolism may mean that H202 initiates AA metabolism, at least in part, by an enzymatic mechanism not involving PLA,. One such alternative mechanism could be that H,O, releases AA via phospholipase C, the activity of which is not increased. but rather inhibited, by PKC [26] . Another potential mechanism is that, instead of ( 
